DISCUSSION
These cases illustrate the diagnostic challenges faced by the endocrine and obstetric team in managing primary hyperparathyroidism (PHPT) during pregnancy. In four cases, the PHPT was secondary to a parathyroid adenoma whilst in two patients, parathyroid hyperplasia was diagnosed. Four patients underwent parathyroidectomy during the second trimester of pregnancy. One patient was diagnosed during her third trimester and was managed conservatively. In three women, hypercalcaemia was detected prior to conception and in one case this was associated with a further miscarriage during the first trimester. This highlights the importance of prompt diagnosis and if PHPT confirmed, appropriate counselling about maternal and fetal risks and the need to expedite surgery. Although case reports describe surgical intervention at different stages during pregnancy, it is generally accepted that the 2 nd trimester is the safest time to operate during pregnancy (1). However, this apparent delay for definitive treatment does expose the mother and foetus to high circulating levels of calcium and increased risk of miscarriage. Furthermore, sestamibi scanning for parathyroid localisation is contraindicated in pregnancy, limiting the opportunity for minimally invasive parathyroidectomy and therefore surgery under local anaesthesia.
Case 5 demonstrates the difficulties in interpreting urine calcium to creatinine ratios (UCCRs) during pregnancy and the differentiation between familial hypocalciuric hypercalcaemia (FHH) and PHPT. FHH should be excluded to avoid an unnecessary parathyroidectomy. Furthermore, during diagnostic work-up, it is important to ensure that patients are vitamin D replete, since low vitamin D reduces urine calcium excretion (2).
During pregnancy, maternal PTH secretion is increased in order to maintain serum ionic calcium levels in the face of expanding extracellular fluid volume, increased urinary excretion and calcium transfer to the growing foetus. Maternal creatinine clearance increases by around 25% during pregnancy (3). A previous study has shown a significant correlation between calcium excretion and creatinine clearance, thought to be due to an increase in glomerular filtration rate (4,5). Although current literature suggests that a UCCR of >0.01 excludes FHH (6, 7, 8) , studies have shown the UCCR can vary significantly in FHH and PHPT. For example, the UCCR ranges from 0.002-0.026 in patients with FHH (9) and 0.0028-0.0624 in patients with PHPT (10). As such, a UCCR cut-off value of 0.02 has been advocated to differentiate between FHH and PHPT, followed by CaSR gene analysis in those with a low UCCR (11, 12) . Importantly, published literature on interpretation of UCCRs to date does not include pregnant women and correct interpretation of the UCCR during pregnancy is unknown.
CONCLUSION
These cases illustrate the difficulties faced in diagnosing and managing women with PHPT during pregnancy, who require close monitoring and definitive management of PHPT. In particular, prompt diagnosis is required and if PHPT confirmed, appropriate counselling should be undertaken about maternal and fetal risks and the need to expedite surgery. In three cases, hypercalcaemia was detected prior to conception and was associated with a history of miscarriages in two of these cases. This highlights the need for counselling and definitive treatment prior to conception. 
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